Advisory Board

Advisory Board


The Asclepius Life Sciences Advisory Board provides independent opinions and recommendations about investment opportunities, market trends, drug development, clinical trials, the regulatory environment and competitive analysis.  Our global thought leaders in investment management, pharmaceuticals, biotechnology, and business consulting enable us to access deep and broad knowledge into public and private life science investment opportunities.

The Advisory Board’s experience spans several organizations including ROSC Global, Monitor Group, Harvard Business School, Johnson & Johnson [NYSE: JNJ], Ares Serono, NeoStem (NASDAQ: NBS), and the Stem for Life Foundation.

The Asclepius Life Sciences Advisory Board was established in 2016. Under the terms of its Charter, the Advisory Board is responsible for periodically examining management’s direction and investment in the Company’s public and private life sciences investments.  The Advisory Board may meet with independent consultants to gain insights and expertise concerning any of our investments and speak directly and independently with any members of the company in discharging its responsibilities.


Mark Fuller

CEO, ROSC Global LLC; Former Chairman and CEO, Monitor Group

Mark B. Fuller is the Chairman and CEO of ROSC Global, a firm providing merchant banking and advisory services to governments, corporations and nonprofits. Mark also sits on a number of for profit and nonprofit boards including the Asian Institute of Management, Teach for All, the Massachusetts Society for the Prevention of Cruelty to Animals, RevJen, and the South Asia Initiative of Harvard University.

From 1983 to 2010, Mark was the founding Chairman and CEO of Monitor Group, an international consulting and investment firm. Previously, he served as an Assistant Professor at the Harvard Graduate School of Business Administration, teaching courses in strategy formulation, implementation, and industry and competitive analysis. He is the author of more than two hundred books, articles and teaching cases. Mark is a graduate, with High Honors, of Harvard College, Harvard Law School and Harvard Business School.


Jules A. Müsing

Pharmaceutical Executive & Advisor

In the course of his career in the Pharmaceutical and Biotechnology Industry, mainly at Johnson & Johnson [NYSE: JNJ], Jules A. Müsing has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology prescription products and technologies and the establishment of corporate strategic alliances.

In this position he negotiated, signed and implemented several multi-million dollar deals with small, medium and large Pharmaceutical and Biotechnology companies on a worldwide basis.

He has more than 40 years’ experience in the pharmaceutical and biotechnology industry, and has been Chief Executive Officer, President and Managing Director of Johnson & Johnson companies in the US and in Europe and of the Swiss-based company Ares Serono in the US. He also has been Executive Vice President of all Ares Serono companies in North- and Latin America.

Additional accomplishments relate to his business development activities in S.E. Asia, where he was instrumental in the establishment of Johnson & Johnson pharmaceutical subsidiaries in Japan, Australia, South Africa, Thailand and other S.E. Asian countries, and to his role of Vice President Marketing International for the Janssen Group of Companies Worldwide.

Mr. Müsing currently serves as a member of the Board of Directors of TherapeuticsMD, Inc. and of Delphi Digital, Inc., and is a member of the Scientific Advisory Board of Noble Financial Capital Markets, an Investment Banking and Merchant Banking boutique in Boca Raton, Florida.

Mr. Müsing previously served as a member of the Board of Directors of Johnson & Johnson companies in Germany, France, Italy and the UK and served as a member of the Management Board of Ortho Biotech, a Johnson & Johnson biotechnology company in the US and in Europe. He also served as Executive Chairman of Pelican Therapeutics, Inc. and as a member of the Board of Directors of iBio, Inc.

Jules A. Müsing received his Postgraduate degree of Master in Sciences from the University of Brussels (Belgium) and his Academic degree in Economic and Financial Sciences – Cum Lauda – from the University of Antwerp (Belgium). He also completed several Postgraduate courses at Harvard University, US and the University of Cambridge, UK. His Honors thesis on the European Monetary Union (1975) was awarded with “ special recognition “ by the Prime Minister of Belgium.

He has been speaker and moderator at several national and international Healthcare conferences and congresses, and is an advisor to a number of Biotechnology and Pharmaceutical companies.


Robin L. Smith, MD, MBA

Chairman & President, Stem for Life Foundation

Dr. Robin L. Smith is recognized as a global thought leader, top medical expert and entrepreneur in one of the fastest growing segments of modern-day medicine –cell therapy research. First as a founder and CEO of NeoStem (NASDAQ: NBS), a leading developer of cell therapy and as the visionary behind the Stem for Life Foundation (SFLF),  Dr. Smith has been able to combine her deep passion for science, entrepreneurism and philanthropy with great success and in the process, has become a key leader in advancing regenerative medicine and in turn, transforming the medical industry.

Dr. Smith currently serves as the President and Chairman of the Board of Directors of The Stem for Life Foundation. Previously, Dr. Smith served as Chief Executive Officer of Caladrius Biosciences Inc (formerly, NeoStem) from June 2, 2006 to January 5, 2015. During her tenure, she pioneered the NeoStem’s innovative business model building proprietary cell therapy development and a successful commercial contract and manufacturing organization.

Dr. Smith is co-author of Cells Without Borders, Biological Solutions to Help Rebuild Healthier, Better Bodies, a book, published in 2016, that describes how virtually any disease that results from malfunctioning, damaged or failing tissues may potentially be cured through a variety of regenerative medicine therapies that draw upon intrinsic healing system of the body.

Dr. Smith currently holds board positions for medical and healthcare based entities including BioXcel Analytics (Member Board of Directors, Chairman of N&G Committee, Member of Audit and Compensation Committee), Rockewell Medical (NASDAQ:  RMTI)  (Member of the Board of Directors), and Signal Genetics (Chairman of the Compensation Committee, Member of Audit and Nominating and Governance Committees).

Dr. Smith holds an MBA in Health Care Administration and Operations Management from University of Pennsylvania – The Wharton School in 1997 and MD from Yale University in 1992.


Steve Glover

Co-Founder & Managing Principal

Steve Glover is the Co-Founder and Managing Principal for Asclepius Life Sciences Fund, L.P.

He has extensive experience and success in biopharmaceutical company turnarounds and growing top line revenues, with a focus on business strategy.  His experience spans Fortune 100, start up and entrepreneurial environments. He has extensive success in turnarounds and growing the top line, with a focus on business strategy, corporate development, product development, commercialization and business optimization. His transaction experience covers over 25 transactions totaling over $10 billion. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management.

Currently Mr. Glover is Co-founder, President and CEO of Variant Pharmaceuticals. Variant is an emerging specialty pharmaceutical company leveraging advanced proprietary technologies to develop two best-in-class drug therapies for patients with rare diseases or other conditions with limited or sub-optimal treatment options. Before founding Variant, Mr. Glover was Co-founder and Chief Business Officer of Coherus BioSciences. Coherus BioSciences is a late-stage biologics platform-company focused on delivering high-quality biosimilar therapeutics. Coherus (CHRS) became a publicly traded company in November of 2014.

Prior to co-founding Coherus, he was the President of Insmed Therapeutic Proteins as well as EVP and Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As EVP and Chief Business Officer he led Insmed’s strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. He earlier held multiple executive roles in sales, marketing and operational roles at Roche Laboratories, Amgen Inc. and IMS Health. Currently Mr. Glover serves on the Board of Directors of Variant Pharmaceuticals, Two-B Pharma and InflamaCore. Additionally Mr. Glover serves as an Executive in Residence at the University of Miami U Innovation Life Sciences Office. Mr. Glover received his B.S. in Marketing from Illinois State University in 1982.


Michael J. Levas

Co-Founder, Senior Managing Principal & Chief Investment Officer

Michael J. Levas is the Co-Founder, Senior Managing Principal & Chief Investment Officer of Asclepius Life Sciences Fund, L.P. and Co-Founder & Chief Investment Officer of Asclepius Ventures, L.P.

Mr. Levas manages investments in multi-asset classes in public and private companies within a construct to de-risk investments.  In the public markets, Asclepius utilizes scientific, financial and technical analysis to manage specific opportunities by identifying and capitalizing on catalyst-driven events.  In the private markets, Asclepius de-risks investments by establishing deep insights on the drug development and approval process in the highest growth areas of Life Sciences including Rare Diseases, Immuno-Oncology, Inflammatory Diseases, Specialty Pharma and Medical Devices.

Mr. Levas has been in the investment management business for over thirty years and is the Founder, former Senior Managing Principal & Chief Investment Officer at the Olympian Group of Investment Management Companies. Previously, he was a VP and Portfolio Manager in the Private Client Group at Lehman Brothers Inc. Prior to that, he was a VP with SG Cowen, UBS PaineWebber, and Bear Stearns where he managed both institutional and retail portfolios. Mr. Levas is the former founder and managing principal of Olympian Securities LLC, & is former licensed Series 24 general securities principal, Series 7 general securities representative, and a current Series 65, investment adviser representative with Olympian Investment Management LLC. Mr. Levas is also the former founder and principal of Olympian Futures LLC, a former (NFA) registered I.B., and a former licensed Series 3 associated person.

Mr. Levas currently holds the Chartered Portfolio Manager (CPM) designation from the American Academy of Financial Management. Mr. Levas completed investment management studies at Harvard Business School, and Global Investment Risk Management at The University of Oxford Said Business School. Additionally, Mr. Levas completed the Hedge Fund Programme at The London Business School. He is a current member of the CFA Institute, Securities Traders Association of NY, and formerly served on the 2008/2009 board of directors of The Hedge Fund Association and was a Federal registered lobbyist for the H.F.A.

Mr. Levas is a frequent conference speaker and commentator on the financial markets & asset management industry. He has been featured throughout the U.S., Canada, Latin America, Europe, Asia and in numerous publications, and media outlets including BusinessWeek, Dow Jones Newswires, Smart Money, Hedge Fund Manager Week, Absolute Return, Canadian Hedge Watch, Euromoney, Economic Times, International Securities Finance, Buy-Side Technology, Securities Industry News, Alternative Investment Review, Advanced Trading, Markets Media Magazine, The Trade News, TradeTech, Waters, Reuters, Bloomberg, CCTV Intl. & National Public Radio.

His specialties include:  momentum trading, actively managed portfolios, multi asset & macro trading, FX trading, listed option trading, call & put writing, and spreads. In addition, Mr. Levas has extensive executive and senior level operational experience in various aspects of founding and managing asset management firms, broker-dealers & hedge funds.

To read Mr. Levas’s full bio on LinkedIn, please click here.

 


 

| Accredited Investors

The information contained in this web site has been prepared solely for accredited investors. It is for informational purposes and is not an offer to sell or purchase or a solicitation of an offer to sell or purchase any interests or shares in any of the funds managed by Asclepius Investment Strategies, LLC Such offers are made only by way of a private offering memorandum delivered to qualified investors.

| Contact

ASCLEPIUS LIFE SCIENCES FUND, L.P.
641 Lexington Avenue, Suite 1337
New York, NY 10022
Phone: (212) 634-6440
Fax: (212) 634-6480